Ten years after BTG weathered a tempest as the FDA erected a barrier to its new treatment for varicose veins, the British biotech company has finally gained U.S. approval for its product and confidently predicts it can register peak sales of $500 million a year.
In an earnings note today, BTG said its Biocompatibles unit had received an FDA warning letter sometime in the last three months for its plant in Oxford, CT. It said it had voluntarily halted production of brachytherapy products.
Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.
In a bid to join the billion-dollar sales club, the UK's BTG has snapped up a pair of operations with new delivery tech and a treatment for deep vein thrombosis for up to $420 million—most of that in cash. And it's selling a chunk of shares to help pay for it all.
Add another failure in AstraZeneca's pipeline. The London-based drug giant and partner BTG have scrapped development of an experimental antibody for sepsis and septic shock after mid-stage study bombed, BTG announced today.
The U.K.'s BTG has won FDA approval for Voraxaze, a new treatment designed to lower methotrexate levels. Methotrexate is a commonly used chemo treatment. This new drug is expected to reap about $15
The UK's BTG has announced plans to acquire Biocompatibles for £177 million, or about $242 million. With the acquisition, BTG gains access to Biocompatibles' oncology products, which include
In another pipeline-building move, California's Onyx Pharmaceuticals has shelled out $320 million for BTG's preclinical anticancer compound, BGC 945. BTG gets $13 million up front and could receive
BTG is buying out Protherics for $388 million in a merger deal that will create the UK's biggest biotech company. In the all-stock buyout, Protherics' shareholders will receive 0.291 new BTG shares